The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
UNIQ Bid: 8.61p Offer: 9.49p
Fundraising and share dilution is one reason ; have a look at the annual reports and rns from the past. http://www.lombardmedical.com/pwpcontrol.php?pwpID=5249 http://www.investegate.co.uk/Index.aspx?searchtype=3&words=lmt
This is slowly being walked back down on no news.
Friday 31 December, 2010 Lombard Medical Tech Board Appointments RNS Number : 8064Y Lombard Medical Technologies PLC 31 December 2010  Lombard Medical Technologies PLC (the "Company") Board Appointments Pursuant to the announcement on 15th December 2010 relating to the appointment of Mr. Simon Hubbert and Dr. Peter Phillip as members of the Company's Board of Directors with effect from 1st January 2011, the Company sets out below the relevant information required for disclosure required pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies: Simon Hubbert, aged 43, joined LMT in 2010 from LMA International, where he was responsible for driving sales in major European markets. Before joining LMA, Simon was a director of Advanced Lifecare Solutions Limited and held a number of senior commercial and business roles at Medtronic from 2001 to 2007 and at Johnson & Johnson from 1994 to 2001. Simon has also worked at Smiths Industries and Vygon UK. Dr. Phillips, aged 52, co-founded Anson Medical in 1995 and ran the company while it developed the Aorfix™ product range. In 2001 he sold Anson Medical to Lombard Medical and remained Managing Director of the division until moving to the United States. He has a PhD from Guy's Hospital London, and was a director of Surgicraft, a UK orthopaedics company. 31 December 2010 - Ends -
what a joke
I was wondering why the share price dropped for no reason last week ; quite obvious now that the MM were fishing for shares in anticipation of today's news
Research Update TIDMLMT RNS Number : 5792Q Lombard Medical Technologies PLC 05 August 2010 ? Lombard Medical Technologies PLC ("Lombard Medical" or "Company") FDA approves the third of six modules for Aorfix(TM) PMA filing Company executing on strategy - further update provided at interim results report on 23 August London, UK, 5 August 2010 - Lombard Medical Technologies PLC (AIM: LMT), a medical device company which develops and markets products for the $1 billion abdominal aortic aneurysm (AAA) repair market, today announced that the U.S. Food and Drug Administration ("FDA") has approved the third of six modules of the Company's Pre-market Approval ("PMA") filing plan for the Aorfix(TM) AAA stent graft. The Company also reports that it continues to make solid progress on the strategy outlined in February of this year when it successfully raised GBP12.1 million (net of expenses) and will update the market further in its interim results statement on 23 August 2010. The third PMA module includes information pertaining to sterilisation, packaging and shelf-life of the Aorfix(TM) stent graft, and is one of five modules covering FDA-required preclinical testing for the device. Modules one and two, which included information on biological testing and non-clinical laboratory studies have already received FDA approval. The Company expects to file the last two non-clinical modules during 2010, with the filing of the final clinical module of the PMA planned for the first half of 2011. John Rush, Chief Executive of Lombard Medical, commented: "Following our fundraising earlier this year, we have remained focused on our commercial opportunity for Aorfix(TM) in Europe by expanding our sales and marketing efforts in the five largest European markets, and also on the activities which we believe will put us in the best position to achieve FDA approval of Aorfix(TM) in the US. The results to date are very encouraging and the FDA's approval of the third PMA module for Aorfix(TM) brings us a step closer towards our goal of securing US approval." Lombard Medical will announce its interim results for the six months ended 30 June 2010 on Monday, 23rd August 2010. There will be an analyst presentation at Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB. Please contact Juliet Edwards at Financial Dynamics on +44 20 7269 7113 for details. An audio webcast of the presentation will be available on Lombard Medical's website at www.lombardmedical.com. - Ends -
http://www.lse.co.uk/SharePrice.asp?shareprice=MEDG&share=medgenics(regs)
Nice bounce, lets hope it holds. 19p+ close would be good.
Hmmm, didn't think that we would fall back as much as this!
This link was posted by jack1236 on advfn http://www.pensions.co.uk/news/2010/Apr/company-pension-payments-linked-to-profits-in-new-deal-97219104.html
Those that sold at the bottom must be kicking themselves now. MM must have triggered a few stop losses on the way. could see some of the shorters getting burned here and selling up soon.
Up 4% on opening, it looks like the market liked the news that Gartmore have bought in the day after the results were out, 6,413,762 shares or 5.585% of the company.
notify that they hold 5.585% . Don't think that they held any shares before. http://www.investegate.co.uk/Article.aspx?id=201004201504094895K
Not sure how relevant this is as it is not a great amount to influence the share price and it states that it is likely to be sub contracted? http://www.publictenders.net/tender/54395
+39.69% rise on the news of disposal sale of 312 million pounds
Try this one- http://tinyurl.com/yfkws9r
Фондът Engel в ликвидна криза Engel Fund in liquidity crisis 28.10.2009 10:25 28.10.2009 10:25 Инвестиционният фонд за имоти Engel East Europe, който развива няколко жилищни проекта в София, се намира в ликвидна криза и смята да се обърне къ&